Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders

Trial Profile

Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 08 May 2014

At a glance

  • Drugs ALLOD 2 (Primary)
  • Indications Facial neuralgia; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Allodynic Therapeutics
  • Most Recent Events

    • 12 Mar 2014 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 23 Dec 2013 Planned End Date changed from 1 Jan 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
    • 23 Dec 2013 Planned initiation date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top